reduced cardiovascular events and reduced the risk of progression to diabetes by 73% in people with established cardiovascular disease and, researchers looked at the effect of semaglutide on the progression of glycemia in people with cardiovascular issues and overweight or obesity, who did not have diabetes.
However, despite the increase in regression to normal glycemic levels, semaglutide did not slow glycemic progression over time, he reported. , the anti-obesity drug reduced MACE by around 20% vs placebo in this high-risk population. At three years, 69.5% of study participants taking semaglutide had a normal glycemic level, compared with 35.8% of those taking placebo . Among those with a normal A1c level at baseline, 9 of 1676 participants receiving semaglutide developed diabetes . For those in the intermediate glycemia group, 0.8% of those taking semaglutide developed diabetes compared with 3.5% of those taking placebo. In the highest-level glycemic group, 3.
The researchers found the reduction in these events was similar to the initial results of the SELECT trial and independent of baseline A1c. The analysis shows that"these beneficial effects of semaglutide will be anticipated across the glycemic continuum," said Lingvay at the ADA meeting. Misra is also interested in how the drugs will be used in younger adults with type 2 diabetes who are increasingly at risk for later cardiovascular consequences.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ForbesTech - 🏆 318. / 59 Read more »